StreetAlpha.app
Home › Stocks › JNJ

Johnson & Johnson (JNJ)

Healthcare
$270.47
▲ +1.25%
LAST CLOSE · NOV 20

Johnson & Johnson makes prescription medicines and medical devices for hospitals, doctors and eye care professionals. It last closed at $270.47 on Nov 20, up 1.25% on the day. The next earnings report for JNJ is expected around Wed, Jan 20, 2027. For the quarter ended Sep 2026, JNJ reported EPS of $0.09 on revenue of $25.40B, with revenue up 5.9% from a year ago. Over its last 8 reports the stock moved an average of 2.3% the session after earnings. Over the last 12 months JNJ insiders bought $258K of stock on the open market and sold $154.4M, according to SEC Form 4 filings.

AI Auto Pilots
Is JNJ in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold JNJ.

Key Stats

Last 12 months
Results
Revenue
$99.3B
+7.8% vs a year ago
Net income
$16.1B
−35.9% vs a year ago
EPS (diluted)
$6.58
−36.4% vs a year ago
Free cash flow
$20.6B
20.7% margin
Valuation
Market cap
$651B
2.41B shares
P/E
41.1
Price over 12 month EPS
Price to sales
6.6
Market cap over revenue
Dividend yield
1.95%
$5.28 a share over 12 months
Balance sheet
Cash & equivalents
$16.9B
At Sep 27
Debt
$35.8B
At Sep 27
Shareholder equity
$81.5B
Buybacks
$7.9B
Last 12 months
CEOJoaquin Duato
Employees138,200 (Nov 1, 2026)
Fiscal year endsJanuary
ExchangeNYSE
Financials history
FY2022: $78.7B$78.7BFY2022FY2023: $80.0B$80.0BFY2023FY2023: $85.2B$85.2BFY2023FY2024: $88.8B$88.8BFY2024FY2025: $94.2B$94.2BFY2025

From JNJ's SEC filings, latest 10-Q for the period ending Sep 27, 2026 (filed Oct 21). Last 12 months adds up the four latest quarters.

Next report
Jan 20
Estimated date · Time not announced
Reported EPS
$0.09
Quarter ended Sep 2026
Year ago EPS
$2.12
−95.8% on a GAAP basis
Revenue
$25.40B
+5.9% vs a year ago
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: $1.41Dec '24Mar 2025: $4.54Mar '25Jun 2025: $2.29Jun '25Sep 2025: $2.12Sep '25Dec 2025: $2.09Dec '25Mar 2026: $2.14Mar '26Jun 2026: $2.27Jun '26Sep 2026: $0.09Sep '26Latest $0.09
Revenue by quarter
Dec 2024: $22.52BDec '24Mar 2025: $21.89BMar '25Jun 2025: $23.74BJun '25Sep 2025: $23.99BSep '25Dec 2025: $24.56BDec '25Mar 2026: $24.06BMar '26Jun 2026: $25.31BJun '26Sep 2026: $25.40BSep '26Latest $25.40B
How JNJ moved after its last 8 reports
Average move the session after a report ±2.3%
Oct 13, 2026Time not announced−5.7%
Jul 15, 2026Time not announced−2.7%
Apr 14, 2026Time not announced+0.9%
Jan 21, 2026Time not announced−0.1%
Oct 14, 2025Time not announced−0.0%
Jul 16, 2025Time not announced+6.2%
Apr 15, 2025Time not announced−0.5%
Jan 22, 2025Time not announced−1.9%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on JNJStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
Analyst calls from around the web
Last 90 days on JNJ: 0 upgrades, 0 downgrades, 0 initiations
JPMorgan Chase & CoTarget raised
Nov 21  

StreetAlpha's curated list of analyst calls collected from around the web. It may be incomplete or inaccurate, is not a consensus and is not advice.

AI Starter and AI Pro
Full analyst coverage on JNJ
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on JNJ

Technical Analysis

JNJ · as of the Nov 20 close · updated each morning
Moving sideways

The stock sits between its 20 and 50 day averages. It is 7% above its 200 day average, so the longer trend is still up. Momentum is fading (RSI 48). The nearest support is the Pivot S1 at $269.13, and the nearest resistance the Pivot at $270.81.

Short trendNeutral
Long trendBullish
MomentumFading
StretchNormal
VolatilityHigh, 2.5%/day
Key levels
$290.2552 week high+7.3%
$275.0120 day average+1.7%
$272.16Pivot R1+0.6%
$271.55Swing high (Sep 14)+0.4%
$270.81Pivot+0.1%
$270.47Last close
$269.13Pivot S1−0.5%
$267.4350 day average−1.1%
$265.28Swing low (Nov 3)−1.9%
$265.07100 day average−2.0%
$250.83200 day average−7.3%
$199.9152 week low−26.1%
Indicators
RSI (14)48.11Middle of its rangeNeutral
MACD2.48Below its signal lineBearish
Stochastic20.7Middle of its rangeNeutral
ADX (14)21.8Weak trend
Williams %R-77.4Oversold below −80, overbought above −20Neutral
CCI (20)-58.5Oversold below −100, overbought above 100Neutral
Rate of change−2.1%Change over 10 sessionsBearish
ATR (14)$6.70Typical daily range, 2.5% of price
MA 10Below
MA 20Below
MA 50Above
MA 100Above
MA 200Above
What happened before, for JNJ

What happened before

See how JNJ did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow JNJ usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How JNJ has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2005.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for JNJHow many large options trades hit JNJ, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

Dark Pool

30D
Prints
Notional
Largest print
Loading…

JNJ Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ●2,083 buying vs 2,009 selling
  • ▼Held by funds -1.1 pts
  • ●Funds holding +36
  • ▼Superinvestors: 1 added, 2 cut
  • ▲Put/call 1.32 to 1.01
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding4,7414,705+0.8%
In funds' top 10325296+9.8%
Held by funds73.7%74.8%−1.1 pts
New / increased171 / 1,912154 / 1,957−1.3%
Reduced / sold out1,906 / 1031,865 / 120+1.2%
Put/call ratio1.011.32−23.3%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See JNJ institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

JNJ Insider Trading

All filings →
Insider trading · 12 months
Insiders are net sellers
Bought$258K1 buy · 1 insider
Sold$154.4M16 sales · 10 insiders
2026-01 sold $22.1M2026-02 sold $58.4M2026-06 sold $2.4M2026-07 sold $5.8M2026-08 sold $52.8M2026-09 sold $9.2M2026-11 sold $3.7MDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Nov 12Elizabeth ForminardEVP, Chief Legal OfficerSale13,072$284.39$3.7M
Sep 2Timothy SchmidEVP, WW Chair, MedTechSale33,597$274.74$9.2M
Aug 17Jennifer L TaubertEVP, WWC. Innovative MedicineSale15,000$263.36$4.0M
Aug 13Joaquin DuatoCEO and Chairman of the BoardSale123,291$261.17$32.2M
Aug 6Elizabeth ForminardEVP, Chief Legal OfficerSale15,918$257.00$4.1M
Aug 5Joaquin DuatoCEO and Chairman of the BoardSale48,480$258.15$12.5M
Every insider buy and sale for JNJ over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See JNJ insider trades →

From SEC Form 4 filings by JNJ's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

JNJ Stock Buybacks

See all S&P 500 buybacks →
Spent, 12 months
$7.9B
1.2% yield
Left in program
—
 
Shares outstanding, 12 months
−0.1%
Fewer shares
Last quarter
$1.7B
Sep 2026
Avg price paid, last quarter
—
6.5M shares bought
S&P 500 rank by spending
#25 of 358
 
Spent each quarter, last 3 yearsTop bar $4.0B
Dec 2023: $216.8M, average price $155.94Mar 2024: $1.5BJun 2024: $135.2MSep 2024: $539.1MDec 2024: $256.6M, average price $160.03Mar 2025: $2.1BJun 2025: $0Sep 2025: $1.9BDec 2025: $1.9B, average price $197.89Mar 2026: $4.0BJun 2026: $222.7MSep 2026: $1.7B
Dec 2023Sep 2026
For membersMonth by month buying, shares and the average price paid each month are shown to AI Starter and AI Pro members.

From the company's 10-Q filed Oct 21, 2026. Quarters are the company's own fiscal quarters. Yield and % of value use the latest close. Buybacks are not a forecast: in our testing, the biggest buyers did about the same as the average S&P 500 stock.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether JNJ is in one of them and how their past JNJ trades turned out.

JNJ in the AI portfolios
Loading…

JNJ News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered JNJ in an article yet. Here's the latest on the wider market.

JNJ in the news

JNJ Congress Trades

All congress trades →
Trades, 12 months
28
Buys
9
32%
Sells
19
68%
People
8
Last filed Nov 19
Who traded JNJ · since 2013
Latest 5 filings of 355
Thomas KeanSell (partial)
$1K – $15KTraded Oct 27, 2026Filed Nov 19, 2026
Ro KhannaSell (partial)
$50K – $100KTraded Oct 7, 2026Filed Nov 5, 2026
Thomas KeanSell (partial)
$1K – $15KTraded Sep 30, 2026Filed Oct 30, 2026
$1K – $15KTraded Sep 25, 2026Filed Oct 7, 2026
$15K – $50KTraded Sep 4, 2026Filed Oct 7, 2026
PersonTypeAmountTradedFiledDelay
Thomas KeanR · NJSell (partial)$1K – $15KOct 27, 2026Nov 19, 202623 d
Ro KhannaD · CASell (partial)$50K – $100KOct 7, 2026Nov 5, 202629 d
Thomas KeanR · NJSell (partial)$1K – $15KSep 30, 2026Oct 30, 202630 d
Ro KhannaD · CABuy$1K – $15KSep 25, 2026Oct 7, 202612 d
Ro KhannaD · CABuy$15K – $50KSep 4, 2026Oct 7, 202633 d

From official House and Senate disclosure reports, filed up to 45 days after the trade and shown in dollar ranges. Not investment advice. Use limited by 5 U.S.C. 13107. About this data

About Johnson & Johnson

Johnson & Johnson is a healthcare company based in New Brunswick, New Jersey, that researches, makes and sells medicines and medical devices. Its Innovative Medicine business offers prescription drugs for conditions such as cancer, immune disorders, mental health conditions, HIV and pulmonary arterial hypertension. Its MedTech business supplies products for heart care, surgery, orthopaedic procedures and vision care. Its customers include hospitals, doctors, retailers, wholesalers and eye care professionals, and it sells in virtually all countries.

Headquarters
New Brunswick, NJ
Founded
1886